Newer therapies - DiabetesontheNet

This site is intended for healthcare professionals only

Newer therapies

Filter:

Albiglutide improves cardiovascular outcomes

This cardiovascular outcome study compared the once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide to placebo in people with type 2 diabetes and cardiovascular disease. Investigators wanted to determine whether albiglutide use was safe and effective in the prevention of cardiovascular death, myocardial infarction or stroke. They enrolled almost 10,000 patients living with diabetes and cardiovascular disease in a multicentred trial and followed them up for a median of 1.6 years. They discovered that albiglutide was superior to placebo in preventing major adverse cardiovascular events in this patient group.

10 Nov 2018

The new ADA/EASD guideline: A huge leap forward in the treatment of type 2 diabetes

Su Down takes a look at the new American Diabetes Association/European Association for the Study of Diabetes consensus report on the management of hyperglycaemia in type 2 diabetes.

5 Nov 2018

Persistence with antidiabetes medication strongly influenced by medication class

Investigators wanted to find out which oral therapies were associated with the best persistence, as medication persistence in type 2 diabetes can contribute to improved glycaemic control. They performed an analysis of a primary-care-based population cohort, comparing median persistence across each class of antidiabetes medication. They found that metformin had the longest median persistence, and that other medications classes varied, sometimes markedly, from this agent. This should be considered when initiating treatments.

7 Jun 2018

The Diabetes Multidisciplinary Team: How do nurse prescribers demonstrate prescribing proficiency?

An explanation of the different types of non-medical prescriber and the guidance and standards that underpin these roles.

31 May 2018

The SIGN 154 diabetes guideline and primary care: it’s not just about the glucose

The key pharmaceutical recommendations for health professionals contained in the new guideline.

31 May 2018

Heart failure and death in new users of SGLT2 inhibitors with and without CVDq

23 Apr 2018

A SIGN of the times: Implementing the new SIGN 154 diabetes guideline in primary care

An overview of the key clinical recommendations contained in the recently published guideline.

8 Mar 2018

Updates from EASD 2017

30 Oct 2017

Sodium–glucose cotransporter 2 inhibitors: Emerging evidence and changes in guidance

30 Oct 2017

CANVAS and EMPA-REG findings support cardiovascular safety of SGLT2 inhibitors

Jill Hill discusses the results of recent studies into this class of drugs.

25 Sep 2017

Breaking news in cardiovascular outcome trials; empagliflozin and stroke; and glycaemic variability in type 1 diabetes

To busy to keep up to date with the latest research? In this series, Lori Berard, a Nurse Manager from Canada, selects the latest papers of interest to diabetes nurses.

25 Sep 2017

Unit 3 – Special care groups: Lifestyle advice and management of obesity in diabetes

13 Sep 2017

A focus on glucagon

4 Sep 2017

Pharmacological approaches to weight loss

4 Sep 2017

CANVAS trial – cardiovascular benefits, amputations and fractures

4 Sep 2017

Liraglutide approved in the EU for the prevention of cardiovascular events

4 Sep 2017

Updates from the ADA conference, the NHS RightCare diabetes pathway and more

21 Jul 2017

PCDS report from the American Diabetes Association’s 77th Scientific Sessions

21 Jul 2017

Resources

For the latest news and articles

Resources

Journals

Useful information

;